Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group

Kidney International

Volumn 91, Issue 5, 2017, Pages 1014-1021

  Trimarchi, Hernán ^a   Barratt, Jonathan ^b   Cattran, Daniel C ^c   Cook, H Terence ^d   Coppo, Rosanna ^e   Haas, Mark ^f   Liu, Zhi Hong ^g   Roberts, Ian S D ^h   Yuzawa, Yukio ⁱ   Zhang, Hong ^j   Feehally, John ^b   Alpers, Charles E ^k   Asunis, Ana María ^k   Barbour, Sean ^k   Becker, Jan U ^k   Ding, Jie ^k   Espino, Gabriella ^k   Ferrario, Franco ^k   Fogo, Agnes ^k   Hladunewich, Michelle ^k   Joh, Kensuke ^k   Katafuchi, Ritsuko ^k   Lv, Jicheng ^k   Matsuzaki, Keiichi ^k   Nakanishi, Koichi ^k   Pani, Antonello ^k   Perera, Ran ^k   Perkowska Ptasinska, Agnieszka ^k   Reich, Heather ^k   Shima, Yuko ^k   Soares, Maria Fernanda ^k   Suzuki, Yusuke ^k   Takahashi, Katsuo ^k   Troyanov, Stéphan ^k   Verhave, Jacobien C ^k   Wang, Suxia ^k   Weening, Jan ^k   Wyatt, Robert ^k   Yoshikawa, Nori ^k   Zeng, Caihong ^k   more..

^a HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^h OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

ⁱ FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j PEKING UNIVERSITY FIRST HOSPITAL   (China)

^k NONE

more..

Author keywords

chronic kidney disease; glomerulonephritis; IgA nephropathy; proteinuria

Indexed keywords

ARTICLE; COHORT ANALYSIS; DISEASE SEVERITY; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; LIMIT OF QUANTITATION; MACROPHAGE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEINURIA; REPRODUCIBILITY; RETROSPECTIVE STUDY; RISK FACTOR; VALIDATION STUDY; ATROPHY; BIOPSY; CLASSIFICATION; CYTOLOGY; FIBROSIS; GLOMERULONEPHRITIS, IGA; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; GLOMERULUS; GLOMERULUS FILTRATION RATE; IMMUNOLOGY; KIDNEY TUBULE; MESANGIUM CELL; PATHOLOGY; RISK ASSESSMENT; SCLEROSIS; TREATMENT OUTCOME; VASCULARIZATION;

IMMUNOSUPPRESSIVE AGENT;

ATROPHY; BIOPSY; FIBROSIS; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, IGA; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY GLOMERULUS; KIDNEY TUBULES; MESANGIAL CELLS; PROTEINURIA; RISK ASSESSMENT; SCLEROSIS; TREATMENT OUTCOME;

EID: 85015786890     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2017.02.003     Document Type: Article

References (38)

1. 1 Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran, D.C., Coppo, R., Cook, H.T., et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 76 (2009), 534–545.
2. 2 Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Coppo, R., Troyanov, S., Camilla, R., et al. The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int 77 (2010), 921–927.
3. 3 Kim, C.H., Lim, B.J., Bae, Y.S., et al. Using the Oxford classification of IgA nephropathy to predict long-term outcomes of Henoch-Schönlein purpura nephritis in adults. Mod Pathol 27 (2014), 972–982.
4. 4 Bellur, S.S., Troyanov, S., Cook, H.T., et al., Working Group of International IgA Nephropathy Network and Renal Pathology Society. Immunostaining findings in IgA nephropathy: correlation with histology and clinical outcome in the Oxford classification patient cohort. Nephrol Dial Transplant 26 (2011), 2533–2536.
5. 5 Joh K, Hashiguchi A, Okonogi H, et al. Histological evaluation on IgA nephropathy in 233 Japanese adult patients: retrospective analysis (abstract; poster no. 12). Oral and poster presented at: the World Congress of Nephrology 2009 Satellite Symposium on IgA Nephropathy. May 22–26, 2009; Milan Italy.
6. 6 Katafuchi, R., Ninomiya, T., Nagata, M., et al. Validation study of oxford classification of IgA nephropathy: The significance of extracapillary proliferation. Clin J Am Soc Nephrol 6 (2011), 2806–2813.
7. 7 Herzenberg, A.M., Fogo, A.B., Reich, H.N., et al. Validation of the Oxford classification of IgA nephropathy. Kidney Int 80 (2011), 310–317.
8. 8 El Karoui, K., Hill, G.S., Karras, A., et al. A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. J Am Soc Nephrol 23 (2012), 137–148.
9. 9 Shi, S.F., Wang, S.X., Jiang, L., et al. Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: validation of the oxford classification. Clin J Am Soc Nephrol 6 (2011), 2175–2184.
10. 10 Alamartine, E., Sauron, C., Laurent, B., et al. The use of the Oxford classification of IgA nephropathy to predict renal survival. Clin J Am Soc Nephrol 6 (2011), 2384–2388.
11. 11 Yau, T., Korbet, S.M., Schwartz, M.M., et al. The Oxford Classification of IgA Nephropathy: a retrospective analysis. Am J Nephrol 34 (2011), 435–444.
12. 12 Edström Halling, S., Söderberg, M.P., Berg, U.B., Predictors of outcome in paediatric IgA nephropathy with regard to clinical and histopathological variables (Oxford classification). Nephrol Dial Transplant 27 (2012), 715–722.
13. 13 Shima, Y., Nakanishi, K., Hama, T., et al. Validity of the Oxford classification of IgA nephropathy in children. Pediatr Nephrol 27 (2012), 783–792.
14. 14 Kataoka, H., Ohara, M., Shibui, K., et al. Overweight and obesity accelerate the progression of IgA nephropathy: prognostic utility of a combination of BMI and histopathological parameters. Clin Exp Nephrol 16 (2012), 706–712.
15. 15 Le, W., Zeng, C.H., Liu, Z., et al. Validation of the Oxford Classification of IgA Nephropathy for pediatric patients from China. BMC Nephrol, 13, 2012, 158.
16. 16 Lee, H., Yi, S.H., Seo, M.S., et al. Validation of the Oxford Classification of IgA Nephropathy: a single-center study in Korean adults. Korean J Intern Med 27 (2012), 293–300.
17. 17 Zeng, C.H., Le, W., Ni, Z., et al. A multicenter application and evaluation of the Oxford Classification of IgA Nephropathy in adult Chinese patients. Am J Kidney Dis 60 (2012), 812–820.
18. 18 Kang, S.H., Choi, S.R., Park, H.S., et al. The Oxford Classification as a predictor of prognosis in patients with IgA nephropathy. Nephrol Dial Transplant 27 (2012), 252–258.
19. 19 Moriyama, T., Nakayama, K., Iwasaki, C., et al. Severity of nephrotic IgA nephropathy according to the Oxford Classification. Int Urol Nephrol 44 (2012), 1177–1184.
20. 20 Gutierrez, E., Zamora, I., Ballarin, J.A., et al. Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol 23 (2012), 1753–1760.
21. 21 Lv, J., Shi, S., Xu, D., et al. Evaluation of the Oxford Classification of IgA nephropathy: a systematic review and meta-analysis. Am J Kidney Dis 62 (2013), 891–899.
22. 22 Nasri, H., Mortazavi, M., Ghorbani, A., et al. Oxford-MEST classification in IgA nephropathy patients: a report from Iran. J Nephropathol 1 (2012), 31–42.
23. 23 Coppo, R., Troyanov, S., Bellur, S.S., et al., VALIGA study of the ERA-EDTA Immunonephrology Working Group. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int 86 (2014), 828–836.
24. 24 Espinosa, M., Ortega, R., Sánchez, M., et al., Spanish Group for Study of Glomerular Diseases (GLOSEN). Association of C4d deposition with clinical outcomes in IgA nephropathy. Clin J Am Soc Nephrol 9 (2014), 897–904.
25. 25 Moriyama, T., Tanaka, K., Iwasaki, C., et al. Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan. PLoS One, 9, 2014, e91756.
26. 26 Park, K.S., Han, S.H., Kie, J.H., et al. Comparison of the Haas and the Oxford classifications for prediction of renal outcome in patients with IgA nephropathy. Hum Pathol 45 (2014), 236–243.
27. 27 Chakera, A., MacEwen, C., Bellur, S.S., et al. Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression. J Nephrol 29 (2016), 367–375.
28. 28 Hou JH, Le WB, Chen N, et al. Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial [e-pub ahead of print]. Am J Kidney Dis. http://dx.doi.org/10.1053/j.ajkd.2016.11.02. Accessed March 15, 2017.
29. 29 Shen, X.H., Liang, S.S., Chen, H.M., et al. Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation. J Nephrol 28 (2015), 441–449.
30. 30 Bellur, S.S., Lepeytre, F., Vorobyeva, O., et al. Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy. Kidney Int 91 (2017), 235–241.
31. 31 Haas M, Verhave JC, Liu ZH, et al. A Multicenter study of the predictive value of crescents in IgA nephropathy. J Am Soc Nephrol., in press.
32. 32 Coppo, R., Lofaro, D., Camilla, R.R., et al. Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort. Pediatr Nephrol 32 (2017), 139–150.
33. 33 Bartosik, L.P., Lajoie, G., Sugar, L., et al. Predicting progression in IgA nephropathy. Am J Kidney Dis 38 (2001), 728–735.
34. 34 Barbour, S.J., Espino-Hernandez, G., Reich, H.N., et al. Oxford Derivation, North American Validation and VALIGA Consortia; Oxford Derivation North American Validation and VALIGA Consortia. The MEST score provides earlier risk prediction in IgA nephropathy. Kidney Int 89 (2016), 167–175.
35. 35 Barbour SJ, Reich H, Suzuki Y, et al. A global platform for prediction modelling in 4915 patients with IgA nephropathy from Asia, Europe and the Americas (Abstract P0626). Presented at: ASN Annual Meeting, 2016, Chicago, IL.
36. 36 Coppo R. Biomarkers and targeted new therapies for IgA nephropathy [e-pub ahead of print]. Pediatr Nephrol. http://dx.doi.org/10.1007/s00467-016-3390-9. Accessed March 15, 2017.
37. 37 Berthoux, F., Suzuki, H., Thibaudin, L., et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 23 (2012), 1579–1587.
38. 38 Wu, Q., Tanaka, H., Hirukawa, T., et al. Characterization and quantification of proliferating cell patterns in endocapillary proliferation. Nephrol Dial Transplant 27 (2012), 3234–3241.